Oramed Pharmaceuticals In... (ORMP)
NASDAQ: ORMP
· Real-Time Price · USD
2.08
-0.04 (-1.89%)
At close: Aug 15, 2025, 3:59 PM
2.07
-0.48%
After-hours: Aug 15, 2025, 05:49 PM EDT
Oramed Pharmaceuticals Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Nov 30, 2021 | Aug 31, 2021 | May 31, 2021 | Feb 28, 2021 |
Revenue | n/a | n/a | n/a | n/a | n/a | 674K | 666K | 681K | 682K | 674K | 666K | 674K | 683K | 681K | 665K |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | n/a | n/a | n/a | n/a | 674K | 666K | 681K | 682K | 674K | 666K | 674K | 683K | 681K | 665K |
Operating Income | -3.09M | -3.13M | -2.96M | -3.88M | -2.89M | -3.79M | -5.21M | -9.74M | -8.19M | -11.42M | -11.25M | -8.06M | -7.41M | -6.12M | -4.87M |
Interest Income | n/a | 14.23M | 5.09M | 18.38M | 435K | 2.48M | 1.6M | n/a | n/a | 350K | 544K | 137K | n/a | n/a | n/a |
Pretax Income | -18.51M | 10.84M | 1.53M | 13.3M | -3.28M | -1.31M | -3.61M | -8.74M | -7.15M | -11.07M | -10.71M | -8.1M | -7.19M | -5.63M | -4.61M |
Net Income | -19.62M | 9.21M | 1.54M | 13.34M | -3.22M | -1.19M | -1.8M | -8.54M | -7.25M | -10.53M | -10.43M | -7.89M | -6.85M | -5.21M | -4.61M |
Selling & General & Admin | 847K | 1.69M | 1.78M | 2.11M | 1.94M | 2.64M | 1.45M | 3.14M | 3.52M | 2.91M | 6.08M | 2.32M | 2.25M | 1.3M | 1.66M |
Research & Development | 2.24M | 1.44M | 1.18M | 1.77M | 957K | 1.82M | 4.43M | 7.28M | 5.35M | 9.18M | 5.84M | 6.41M | 5.84M | 5.5M | 3.87M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 3.09M | 3.13M | 2.96M | 3.88M | 2.89M | 4.46M | 5.87M | 10.42M | 8.87M | 12.09M | 11.92M | 8.73M | 8.09M | 6.8M | 5.53M |
Interest Expense | 15.42M | 261K | 592K | 1.21M | 826K | n/a | n/a | n/a | 1.04M | 350K | 544K | 175K | n/a | 493K | 260K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | -663K | 192K | 184K | 418K | 463K | 380K | 590K | 585K | n/a | n/a | n/a |
Cost & Expenses | 3.09M | 3.13M | 2.96M | 3.88M | 2.89M | 4.46M | 5.87M | 10.42M | 8.87M | 12.09M | 11.92M | 8.73M | 8.09M | 6.8M | 5.53M |
Income Tax Expense | 1.13M | 1.63M | n/a | n/a | 373K | -119K | -1.81M | -193K | 100K | -534K | -283K | -208K | -333K | -418K | -260K |
Shares Outstanding (Basic) | 40.9M | 40.96M | 40.84M | 40.38M | 40.45M | 40.23M | 40.04M | 39M | 39.1M | 38.8M | 38.68M | 36.67M | 29.93M | 29.93M | 27M |
Shares Outstanding (Diluted) | 40.9M | 41.59M | 41.56M | 40.51M | 40.45M | 40.23M | 40.04M | 39M | 39.1M | 38.8M | 38.68M | 36.67M | 29.93M | 29.93M | 27M |
EPS (Basic) | -0.48 | 0.22 | 0.04 | 0.33 | -0.08 | -0.03 | -0.04 | -0.22 | -0.19 | -0.27 | -0.27 | -0.22 | -0.23 | -0.17 | -0.17 |
EPS (Diluted) | -0.48 | 0.22 | 0.04 | 0.33 | -0.08 | -0.03 | -0.04 | -0.22 | -0.19 | -0.27 | -0.27 | -0.22 | -0.23 | -0.17 | -0.17 |
EBITDA | -3.04M | 11.15M | 2.18M | 14.56M | -2.4M | -3.74M | -5.17M | -6.79M | -8.17M | -11.4M | -11.24M | -7.91M | -7.39M | -6.09M | -4.84M |
EBIT | -3.09M | 11.1M | 2.13M | 14.51M | n/a | -3.79M | -5.21M | -9.74M | -8.19M | -11.42M | -11.25M | n/a | -7.41M | -6.12M | -4.87M |
Depreciation & Amortization | 52K | 54K | 56K | 53K | 54K | 52K | 37K | 2.95M | 15K | 15K | 11K | 12K | 19K | 28K | 28K |